 |
42 Diseases |  |
111 Trials |
|
111 Trials |  |
1691 News |  |
| «12345678910111213...3132» |
- | Keytruda (pembrolizumab) / Merck (MSD), Avastin (bevacizumab) / Roche
Trial completion date, Combination therapy: PEMBOV: Pembrolizumab in Combination With Bevacizumab and Pegylated Liposomal Doxorubicin in Patients With Ovarian Cancer (clinicaltrials.gov) - Feb 13, 2023
P1, N=47, Active, not recruiting, Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Trial completion date: Jun 2024 --> Apr 2023
- ||| batiraxcept (AVB-500) / Aravive
Trial completion: AVB500-OC-002: Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer (clinicaltrials.gov) - Feb 13, 2023
P1b/2, N=53, Completed, Sponsor: Aravive, Inc.
Trial completion date: Jun 2024 --> Apr 2023 Active, not recruiting --> Completed
- || Lynparza (olaparib) / Merck (MSD), AstraZeneca
P2 data, Journal, BRCA Biomarker, PARP Biomarker: Clinical and molecular signature of survival and resistance to olaparib plus pegylated liposomal doxorubicin in platinum-resistant ovarian cancer: a stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601. (Pubmed Central) - Feb 9, 2023
High neutrophil/lymphocyte ratio at platinum-resistant relapse indicated poor prognosis in patients treated with olaparib plus pegylated liposomal doxorubicin. A multifactorial clinical signature was more precise than single variables for implying the prognosis and may help in therapeutic assignment after further validation in large prospective cohorts.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Liposomal Doxorubicin: the Sphingomyelin/Cholesterol System Significantly Enhances the Antitumor Efficacy of Doxorubicin. (Pubmed Central) - Feb 9, 2023
A multifactorial clinical signature was more precise than single variables for implying the prognosis and may help in therapeutic assignment after further validation in large prospective cohorts. Although Doxil
- |||| Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date, Metastases: Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) (clinicaltrials.gov) - Feb 9, 2023
P3, N=800, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Although Doxil Trial completion date: Oct 2027 --> Jul 2028 | Trial primary completion date: Oct 2027 --> Jul 2028
- | Libtayo (cemiplimab-rwlc) / Regeneron
Trial completion date, Trial primary completion date, Metastases: Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer (clinicaltrials.gov) - Feb 8, 2023
P2, N=36, Recruiting, Sponsor: Medical College of Wisconsin
Trial completion date: Oct 2027 --> Jul 2028 | Trial primary completion date: Oct 2027 --> Jul 2028 Trial completion date: Mar 2024 --> Jan 2025 | Trial primary completion date: Mar 2023 --> Jan 2024
- | Zynlonta (loncastuximab tesirine-lpyl) / Overland ADCT BioPharma
Enrollment open, Combination therapy: Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies (clinicaltrials.gov) - Feb 8, 2023
P1, N=33, Recruiting, Sponsor: Medical College of Wisconsin
Trial completion date: Mar 2024 --> Jan 2025 | Trial primary completion date: Mar 2023 --> Jan 2024 Not yet recruiting --> Recruiting
- | Trial suspension, Combination therapy: NRG-GY023: Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents (clinicaltrials.gov) - Feb 3, 2023
P2, N=164, Suspended, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Recruiting --> Suspended
- | Keytruda (pembrolizumab) / Merck (MSD)
New P3 trial, Checkpoint inhibition: A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma (clinicaltrials.gov) - Feb 3, 2023
P3, N=334, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | peposertib (M3814) / EMD Serono
New P1 trial, Combination therapy, Metastases: ETCTN 10563: Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma (clinicaltrials.gov) - Feb 3, 2023
P1, N=66, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | carboplatin / Generic mfg., cyclophosphamide / Generic mfg., paclitaxel / Generic mfg.
Trial completion, Trial completion date: Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer (clinicaltrials.gov) - Feb 1, 2023
P2, N=29, Completed, Sponsor: University of Wisconsin, Madison
Recruiting --> Suspended Active, not recruiting --> Completed | Trial completion date: Oct 2022 --> Feb 2022
- pegylated liposomal doxorubicin / Generic mfg., ifosfamide / Generic mfg.
Pegylated liposomal doxorubicin combined with ifosfamide for advanced soft tissue sarcomas: A phase I dose-escalation study (Foyer) - Jan 30, 2023 - Abstract #SarcomaRC2023SARCOMA_RC_286;
- pegylated liposomal doxorubicin / Generic mfg.
A single-arm, open, multicenter study to evaluate pegylated liposomal doxorubicin in the treatment of osteosarcoma (Foyer) - Jan 30, 2023 - Abstract #SarcomaRC2023SARCOMA_RC_281;
- | pegylated liposomal doxorubicin / Generic mfg.
Trial initiation date, Combination therapy: Combination Therapy for Recurrent Ovarian Cancer (clinicaltrials.gov) - Jan 30, 2023
P1/2, N=72, Not yet recruiting, Sponsor: Sham Sunder Kakar
Active, not recruiting --> Completed | Trial completion date: Oct 2022 --> Feb 2022 Initiation date: Nov 2022 --> Mar 2023
- || pegylated liposomal doxorubicin / Generic mfg., Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, gemcitabine / Generic mfg.
So you think it could be an option for me? I am on the 3 IV chemo (Erubilin), Doxil Gemzar). Enhertu was working but developed ILD. I have the ESR1 mutation..feeling desperate. (Twitter) - Jan 29, 2023
- | pegylated liposomal doxorubicin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Biomarker, Trial completion date: Study to Assess TOPO2A as a Biomarker for Sensitivity to Doxorubicin/Doxil in Soft Tissue Sarcoma (clinicaltrials.gov) - Jan 27, 2023
P=N/A, N=24, Active, not recruiting, Sponsor: Fox Chase Cancer Center
Initiation date: Nov 2022 --> Mar 2023 Trial completion date: Dec 2022 --> May 2023
- || Lynparza (olaparib) / Merck (MSD), AstraZeneca
Trial completion: ROLANDO: Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin (clinicaltrials.gov) - Jan 27, 2023
P2, N=32, Completed, Sponsor: Grupo Espa
Trial completion date: Dec 2022 --> May 2023 Active, not recruiting --> Completed
- | disulfiram / Generic mfg.
Enrollment open: Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas (clinicaltrials.gov) - Jan 26, 2023
P1, N=24, Recruiting, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | pegylated liposomal doxorubicin / Generic mfg., paclitaxel / Generic mfg.
Trial initiation date, Head-to-Head: Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma (clinicaltrials.gov) - Jan 25, 2023
P3, N=130, Not yet recruiting, Sponsor: AIDS Malignancy Consortium
Not yet recruiting --> Recruiting Initiation date: Dec 2022 --> Jun 2023
- || AZD7648 / AstraZeneca
Trial completion, Combination therapy, Monotherapy, Metastases: A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers. (clinicaltrials.gov) - Jan 18, 2023
P1/2, N=30, Completed, Sponsor: AstraZeneca
Initiation date: Dec 2022 --> Jun 2023 Active, not recruiting --> Completed
- | pegylated liposomal doxorubicin / Generic mfg.
Journal: Cell-specific cargo delivery using synthetic bacterial spores. (Pubmed Central) - Jan 15, 2023
Target cells actively internalize and then traffic bound SSHELs to acidic compartments, whereupon the cargo is released to the cytosol in a pH-dependent manner. We propose that SSHELs represent a versatile strategy for targeted drug delivery, especially in cancer settings.
- pegylated liposomal doxorubicin / Generic mfg.
Targeted delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment of high-risk childhood leukemia () - Jan 13, 2023 - Abstract #LCC2023LCC_82;
Targeted delivery of Caelyx using BsAbs further enhanced leukemia suppression and extended overall survival by up to three- fold in patient-derived xenograft models of high-risk childhood leukemia. Our methodology employing BsAbs therefore represent an attractive targeting platform to potentiate the therapeutic efficacy and safety of liposomal drugs for improved treatment of high-risk leukemia.
- | Journal, BRCA Biomarker: Efficacy of chemotherapy according to BRCA status in patients with high-grade serous ovarian carcinoma at first platinum-sensitive relapse. (Pubmed Central) - Jan 12, 2023
Our methodology employing BsAbs therefore represent an attractive targeting platform to potentiate the therapeutic efficacy and safety of liposomal drugs for improved treatment of high-risk leukemia. While treatment with carboplatin/paclitaxel, carboplatin/gemcitabine, and carboplatin/pegylated liposomal doxorubicin shows comparable efficacy in BRCA mutated patients, treatment with carboplatin/paclitaxel appears to be more effective than carboplatin/gemcitabine and carboplatin/pegylated liposomal doxorubicin in BRCA wild type patients with high-grade serous ovarian cancers at first platinum-sensitive relapse.
- | Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial completion date, Trial primary completion date: 19-C-0103: Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) (clinicaltrials.gov) - Jan 10, 2023
P2, N=65, Recruiting, Sponsor: National Cancer Institute (NCI)
While treatment with carboplatin/paclitaxel, carboplatin/gemcitabine, and carboplatin/pegylated liposomal doxorubicin shows comparable efficacy in BRCA mutated patients, treatment with carboplatin/paclitaxel appears to be more effective than carboplatin/gemcitabine and carboplatin/pegylated liposomal doxorubicin in BRCA wild type patients with high-grade serous ovarian cancers at first platinum-sensitive relapse. Trial completion date: Jul 2025 --> Jul 2026 | Trial primary completion date: Jul 2023 --> Jul 2025
- | Talidox (doxorubicin liposomal) / Innomedica
Enrollment open, Metastases: SAKK 65/16: TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jan 10, 2023
P1, N=30, Recruiting, Sponsor: Swiss Group for Clinical Cancer Research
Trial completion date: Jul 2025 --> Jul 2026 | Trial primary completion date: Jul 2023 --> Jul 2025 Active, not recruiting --> Recruiting
- | pegylated liposomal doxorubicin / Generic mfg.
Trial completion, Metastases: Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy (clinicaltrials.gov) - Jan 10, 2023
P2, N=24, Completed, Sponsor: University of Arizona
Active, not recruiting --> Recruiting Active, not recruiting --> Completed
- | pegylated liposomal doxorubicin / Generic mfg.
Journal, Metastases: A multicenter randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Caelyx in advanced breast cancer. (Pubmed Central) - Jan 7, 2023
Bioequivalence between the test and the reference products was established for free and encapsulated doxorubicin. http://www.chinadrugtrials.org.cn, identifier [CTR20210375].
- | Avastin (bevacizumab) / Roche
Trial completion date, Trial primary completion date, Metastases: Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer (clinicaltrials.gov) - Jan 5, 2023
P1, N=52, Recruiting, Sponsor: M.D. Anderson Cancer Center
http://www.chinadrugtrials.org.cn, identifier [CTR20210375]. Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
- Avastin (bevacizumab) / Roche
CARDIOTOXICITY OF COMBINED PEGYLATED LIPOSOMAL DOXORUBICIN AND BEVACIZUMAB THERAPY (Poster Hall_Hall F) - Jan 4, 2023 - Abstract #ACCWCC2023ACC_WCC_8113;
Combination therapy with PLD and bevacizumab was associated with increased cardiovascular events compared to PLD alone in the real-world setting. Prospective studies are needed to validate our results.
- || pegylated liposomal doxorubicin / Generic mfg.
Trial completion date, Trial initiation date, Trial primary completion date, Metastases: Doxil/Caelyx BE Study (clinicaltrials.gov) - Jan 4, 2023
P1, N=36, Not yet recruiting, Sponsor: Baxter Healthcare Corporation
Prospective studies are needed to validate our results. Trial completion date: Jul 2023 --> Oct 2023 | Initiation date: Nov 2022 --> Feb 2023 | Trial primary completion date: Jul 2023 --> Oct 2023
- || Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
Trial completion: Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov) - Jan 4, 2023
P1/2, N=28, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial completion date: Jul 2023 --> Oct 2023 | Initiation date: Nov 2022 --> Feb 2023 | Trial primary completion date: Jul 2023 --> Oct 2023 Active, not recruiting --> Completed
- | maplirpacept (TTI-622) / Pfizer
Trial completion date, Trial primary completion date, Combination therapy: Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer (clinicaltrials.gov) - Dec 29, 2022
P2, N=50, Recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Trial completion date: Feb 2026 --> Jul 2026 | Trial primary completion date: Feb 2025 --> Jul 2025
- | CDX-1140 / Celldex, Mobista (CDX-301) / Celldex
Trial completion date, Trial primary completion date, Combination therapy, Metastases: CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer (clinicaltrials.gov) - Dec 28, 2022
P1, N=45, Recruiting, Sponsor: University of Texas Southwestern Medical Center
Trial completion date: Feb 2026 --> Jul 2026 | Trial primary completion date: Feb 2025 --> Jul 2025 Trial completion date: Oct 2024 --> Apr 2026 | Trial primary completion date: Oct 2024 --> Apr 2025
- | pegylated liposomal doxorubicin / Generic mfg.
Journal, Metastases: A propensity score-weighted study comparing a two- versus four-weekly pegylated liposomal doxorubicin regimen in metastatic breast cancer. (Pubmed Central) - Dec 24, 2022
PLD appeared to be a well-tolerated drug in this heavily pretreated MBC population. The efficacy and safety of the 2-weekly schedule did not provide any advantage, suggesting no interest in changing the registered regimen.
- | Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma
Journal: Trabectedin plus pegylated liposomal doxorubicin in patients with disease progression after PARP inhibitor maintenance: a real-life case-control study. (Pubmed Central) - Dec 24, 2022
Pegylated liposomal doxorubicin/trabectedin might be an alternative option to platinum-based treatment in patients experiencing disease progression during PARP inhibitor maintenance with an acceptable toxicity profile. This might be a therapeutic option in this setting, sparing platinum compounds for subsequent relapse.
- || anetumab ravtansine (BAY 94-9343) / Bayer
P1 data, Journal, Combination therapy: Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study. (Pubmed Central) - Dec 24, 2022
P1
Anetumab ravtansine and pegylated liposomal doxorubicin showed tolerability and promising clinical activity. These results established the dose schedule and the mesothelin-positive target population of this combination for a phase III study in platinum-resistant ovarian cancer.
- ||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Retrospective data, Review, Adverse events: Cardiovascular adverse events associated with cyclophosphamide, pegylated liposomal doxorubicin, vincristine, and prednisone with or without rituximab ((R)-CDOP) in non-Hodgkin's lymphoma: A systematic review and meta-analysis. (Pubmed Central) - Dec 20, 2022
In addition, this study found the (R)-CDOP regimen was no less efficacious than the (R)-CHOP regimen in the treatment of non-Hodgkin's lymphoma. These findings need to be validated by higher-quality research because of the limited number and quality of included studies.
- ||| Duomeisu (pegylated liposomal doxorubicin) / CSPC Pharma, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New trial: easy laugh: To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study (clinicaltrials.gov) - Dec 19, 2022
P=N/A, N=204, Recruiting, Sponsor: Shanghai Pudong Hospital
- | pegylated liposomal doxorubicin / Generic mfg.
Journal, Tumor microenvironment: Delineating the tumour microenvironment response to lipid nanoparticle formulation. (Pubmed Central) - Dec 16, 2022
Here we conducted a cytodistribution analysis on Doxorubicin-treated and Doxil-treated tumours to delineate the differences between the small molecule therapeutic Doxorubicin and its packaged liposomal Doxil...We conclude that the fate and behaviour of the nanocarrier influence its effectiveness as a cancer therapy. Further investigations on the interactions between different nanoparticle designs and the tumour microenvironment components will lead to more precise engineering of nanocarriers to selectively kill tumour cells and prolong the therapeutic effect.
- | Neulasta (pegfilgrastim) / Roche
Trial completion: PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma (clinicaltrials.gov) - Dec 15, 2022
P=N/A, N=70, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
Further investigations on the interactions between different nanoparticle designs and the tumour microenvironment components will lead to more precise engineering of nanocarriers to selectively kill tumour cells and prolong the therapeutic effect. Active, not recruiting --> Completed
- || azenosertib (ZN-c3) / Zentalis Pharma
Trial completion date, Trial primary completion date, Combination therapy: ZN-c3-002: A Study of ZN-c3 in Patients With Ovarian Cancer (clinicaltrials.gov) - Dec 14, 2022
P1b, N=140, Recruiting, Sponsor: K-Group Beta
Active, not recruiting --> Completed Trial completion date: Jan 2023 --> Aug 2024 | Trial primary completion date: Oct 2022 --> Jan 2024
- | pegylated liposomal doxorubicin / Generic mfg.
Journal: Pyridoxine Is Effective for Preventing Hand-Foot Syndrome Induced by Pegylated Liposomal Doxorubicin for Multiple Myeloma: The Results of a Randomized Study. (Pubmed Central) - Dec 14, 2022
Further research with a placebo-controlled design is recommended. ChiCTR2100050294.
- || Tecentriq (atezolizumab) / Roche
Clinical, P2b data, Journal: Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial. (Pubmed Central) - Dec 10, 2022
P2
The progression-free proportion after 15 months was 14.7% (5/34; 95% CI 6.4-30.1%) in the atezo-chemo arm versus 0% in the placebo-chemo arm. The addition of atezolizumab to PLD/cyclophosphamide was tolerable with an indication of clinical benefit, and the findings warrant further investigation of PD1/PD-L1 blockers in combination with immunomodulatory chemotherapy.
- | Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial completion date, Trial primary completion date: Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma (clinicaltrials.gov) - Dec 8, 2022
P1, N=93, Recruiting, Sponsor: National Cancer Institute (NCI)
The addition of atezolizumab to PLD/cyclophosphamide was tolerable with an indication of clinical benefit, and the findings warrant further investigation of PD1/PD-L1 blockers in combination with immunomodulatory chemotherapy. Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Jun 2023 --> Jun 2024
- || elraglusib (9-ING-41) / Actuate Therap
Phase classification, Trial completion date, Trial primary completion date, Metastases: Actuate 1801: 9-ING-41 in Patients With Advanced Cancers (clinicaltrials.gov) - Dec 7, 2022
P2, N=350, Recruiting, Sponsor: Actuate Therapeutics Inc.
Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Jun 2023 --> Jun 2024 Phase classification: P1/2 --> P2 | Trial completion date: Nov 2023 --> Nov 2025 | Trial primary completion date: Nov 2022 --> Nov 2024
- || pegylated liposomal doxorubicin / Generic mfg.
When can we expect it to be approved..I’m ESR1 and on Doxil and all I have left is toxic chemos (Twitter) - Nov 30, 2022
- bortezomib / Generic mfg., dexamethasone / Generic mfg.
MM-SZ01 Study: A Prospective, Randomized, Controlled, Multicenter Phase III Clinical Study Which Compared Polyethylene Glycol Liposomal Doxorubicin Versus Doxorubicin Combined with Bortezomib and Dexamethasone (PDD regimen vs PAD regimen) in the Treatment of Newly Diagnosed Multiple Myeloma in China () - Nov 29, 2022 - Abstract #ASH2022ASH_7733;
The 6-course PDD regimen had better PFS and OS than PAD in the non-transplant population. Therefore, replacing PAD with the PDD regimen of pegylated liposomal doxorubicin in the initial induction regimen is beneficial in both transplantable and non-transplantable MM patients.
- pegylated liposomal doxorubicin / Generic mfg., gemcitabine / Generic mfg.
Clinical Outcomes of Single-Agent Chemotherapy in a Diverse Cohort of Patients with Recalcitrant Cutaneous T-Cell Lymphoma () - Nov 29, 2022 - Abstract #ASH2022ASH_7434;
The overall response rates were lower than the early clinical trials, and we are investigating outcome-related clinical characteristics in this cohort. These observations should be further investigated through multicenter studies of diverse cohorts of patients.
- | pegylated liposomal doxorubicin / Generic mfg.
Journal, IO biomarker: Depletion of gut microbiota improves the therapeutic efficacy of cancer nanomedicine. (Pubmed Central) - Nov 29, 2022
We showed that gut microbiota depletion led to enhanced tumor vascular permeability, which allowed a larger amount of LipoDox nanoparticles to accumulate in the tumor, leading to better long-term effects. Our results suggest that gut microbiota modulation may be exploited in combination with available nanomedicine-based therapeutics to improve cancer diagnosis, therapeutic efficacy and outcome.
- || Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, Avastin (bevacizumab) / Roche
Clinical, Retrospective data, Review: A comprehensive comparison of medication strategies for platinum-sensitive recurrent ovarian cancer: A Bayesian network meta-analysis. (Pubmed Central) - Nov 29, 2022
Trabectedin plus PLD might be a potential alternative treatment strategy for the partially platinum-sensitive subpopulation with intolerance to platinum. Systematic Review Registration: [https://www.crd.york.ac.uk/prospero/display_record.php?], identifier [CRD42022326573].